Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Reproducible bioinformatics project: a community for reproducible bioinformatics analysis pipelines.

Kulkarni N, Alessandrì L, Panero R, Arigoni M, Olivero M, Ferrero G, Cordero F, Beccuti M, Calogero RA.

BMC Bioinformatics. 2018 Oct 15;19(Suppl 10):349. doi: 10.1186/s12859-018-2296-x.

2.

MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells.

Cerna K, Oppelt J, Chochola V, Musilova K, Seda V, Pavlasova G, Radova L, Arigoni M, Calogero RA, Benes V, Trbusek M, Brychtova Y, Doubek M, Mayer J, Pospisilova S, Mraz M.

Leukemia. 2018 Aug 15. doi: 10.1038/s41375-018-0230-x. [Epub ahead of print]

PMID:
30111844
3.

Posterior pelvic ring fractures: Intraoperative 3D-CT guided navigation for accurate positioning of sacro-iliac screws.

Ghisla S, Napoli F, Lehoczky G, Delcogliano M, Habib N, Arigoni M, Filardo G, Candrian C.

Orthop Traumatol Surg Res. 2018 Nov;104(7):1063-1067. doi: 10.1016/j.otsr.2018.07.006. Epub 2018 Aug 3.

PMID:
30081217
4.

An algorithm to avoid missed open-book pelvic fractures.

Habib N, Filardo G, Delcogliano M, Arigoni M, Candrian C.

Eur Rev Med Pharmacol Sci. 2018 May;22(10):2973-2977. doi: 10.26355/eurrev_201805_15052.

5.

microRNA profiles in urine by next-generation sequencing can stratify bladder cancer subtypes.

Pardini B, Cordero F, Naccarati A, Viberti C, Birolo G, Oderda M, Di Gaetano C, Arigoni M, Martina F, Calogero RA, Sacerdote C, Gontero P, Vineis P, Matullo G.

Oncotarget. 2018 Apr 17;9(29):20658-20669. doi: 10.18632/oncotarget.25057. eCollection 2018 Apr 17.

6.

Luminal breast cancer-specific circular RNAs uncovered by a novel tool for data analysis.

Coscujuela Tarrero L, Ferrero G, Miano V, De Intinis C, Ricci L, Arigoni M, Riccardo F, Annaratone L, Castellano I, Calogero RA, Beccuti M, Cordero F, De Bortoli M.

Oncotarget. 2018 Feb 19;9(18):14580-14596. doi: 10.18632/oncotarget.24522. eCollection 2018 Mar 6.

7.

Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs' Revolution for Immunotherapy.

Barutello G, Rolih V, Arigoni M, Tarone L, Conti L, Quaglino E, Buracco P, Cavallo F, Riccardo F.

Int J Mol Sci. 2018 Mar 10;19(3). pii: E799. doi: 10.3390/ijms19030799. Review.

8.

Small non-coding RNA profiling in human biofluids and surrogate tissues from healthy individuals: description of the diverse and most represented species.

Ferrero G, Cordero F, Tarallo S, Arigoni M, Riccardo F, Gallo G, Ronco G, Allasia M, Kulkarni N, Matullo G, Vineis P, Calogero RA, Pardini B, Naccarati A.

Oncotarget. 2017 Dec 14;9(3):3097-3111. doi: 10.18632/oncotarget.23203. eCollection 2018 Jan 9.

9.

Long non-coding and coding RNAs characterization in Peripheral Blood Mononuclear Cells and Spinal Cord from Amyotrophic Lateral Sclerosis patients.

Gagliardi S, Zucca S, Pandini C, Diamanti L, Bordoni M, Sproviero D, Arigoni M, Olivero M, Pansarasa O, Ceroni M, Calogero R, Cereda C.

Sci Rep. 2018 Feb 5;8(1):2378. doi: 10.1038/s41598-018-20679-5.

10.

SeqBox: RNAseq/ChIPseq reproducible analysis on a consumer game computer.

Beccuti M, Cordero F, Arigoni M, Panero R, Amparore EG, Donatelli S, Calogero RA.

Bioinformatics. 2018 Mar 1;34(5):871-872. doi: 10.1093/bioinformatics/btx674.

11.

Angiomotin like-1 is a novel component of the N-cadherin complex affecting endothelial/pericyte interaction in normal and tumor angiogenesis.

Zheng Y, Zhang Y, Barutello G, Chiu K, Arigoni M, Giampietro C, Cavallo F, Holmgren L.

Sci Rep. 2016 Jul 28;6:30622. doi: 10.1038/srep30622.

12.

A hypoxic signature marks tumors formed by disseminated tumor cells in the BALB-neuT mammary cancer model.

Msaki A, Pastò A, Curtarello M, Arigoni M, Barutello G, Calogero RA, Macagno M, Cavallo F, Amadori A, Indraccolo S.

Oncotarget. 2016 May 31;7(22):33081-95. doi: 10.18632/oncotarget.8859.

13.

Immunotargeting of Antigen xCT Attenuates Stem-like Cell Behavior and Metastatic Progression in Breast Cancer.

Lanzardo S, Conti L, Rooke R, Ruiu R, Accart N, Bolli E, Arigoni M, Macagno M, Barrera G, Pizzimenti S, Aurisicchio L, Calogero RA, Cavallo F.

Cancer Res. 2016 Jan 1;76(1):62-72. doi: 10.1158/0008-5472.CAN-15-1208. Epub 2015 Nov 13.

14.

Novel insights into Notum and glypicans regulation in colorectal cancer.

De Robertis M, Arigoni M, Loiacono L, Riccardo F, Calogero RA, Feodorova Y, Tashkova D, Belovejdov V, Sarafian V, Cavallo F, Signori E.

Oncotarget. 2015 Dec 1;6(38):41237-57. doi: 10.18632/oncotarget.5652.

15.

Antitumor immunization of mothers delays tumor development in cancer-prone offspring.

Barutello G, Curcio C, Spadaro M, Arigoni M, Trovato R, Bolli E, Zheng Y, Ria F, Quaglino E, Iezzi M, Riccardo F, Holmgren L, Forni G, Cavallo F.

Oncoimmunology. 2015 Feb 3;4(5):e1005500. eCollection 2015 May.

16.

Cluster analysis of quantitative parametric maps from DCE-MRI: application in evaluating heterogeneity of tumor response to antiangiogenic treatment.

Longo DL, Dastrù W, Consolino L, Espak M, Arigoni M, Cavallo F, Aime S.

Magn Reson Imaging. 2015 Jul;33(6):725-36. doi: 10.1016/j.mri.2015.03.005. Epub 2015 Mar 31.

17.

Chimeric DNA Vaccines: An Effective Way to Overcome Immune Tolerance.

Riccardo F, Bolli E, Macagno M, Arigoni M, Cavallo F, Quaglino E.

Curr Top Microbiol Immunol. 2017;405:99-122. doi: 10.1007/82_2014_426.

PMID:
25294003
18.

Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers.

Riccardo F, Arigoni M, Buson G, Zago E, Iezzi M, Longo D, Carrara M, Fiore A, Nuzzo S, Bicciato S, Nanni P, Landuzzi L, Cavallo F, Calogero R, Quaglino E.

BMC Genomics. 2014;15 Suppl 3:S1. doi: 10.1186/1471-2164-15-S3-S1. Epub 2014 May 6.

19.

CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA.

Riccardo F, Iussich S, Maniscalco L, Lorda Mayayo S, La Rosa G, Arigoni M, De Maria R, Gattino F, Lanzardo S, Lardone E, Martano M, Morello E, Prestigio S, Fiore A, Quaglino E, Zabarino S, Ferrone S, Buracco P, Cavallo F.

Clin Cancer Res. 2014 Jul 15;20(14):3753-62. doi: 10.1158/1078-0432.CCR-13-3042. Epub 2014 May 29.

20.

Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice.

Bandini S, Curcio C, Macagno M, Quaglino E, Arigoni M, Lanzardo S, Hysi A, Barutello G, Consolino L, Longo DL, Musiani P, Forni G, Iezzi M, Cavallo F.

Oncoimmunology. 2013 Sep 1;2(9):e26137. Epub 2013 Sep 12.

21.

Recombinant human lactoferrin induces human and mouse dendritic cell maturation via Toll-like receptors 2 and 4.

Spadaro M, Montone M, Arigoni M, Cantarella D, Forni G, Pericle F, Pascolo S, Calogero RA, Cavallo F.

FASEB J. 2014 Jan;28(1):416-29. doi: 10.1096/fj.13-229591. Epub 2013 Oct 2.

PMID:
24088817
22.

Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer.

Cardillo I, Spugnini EP, Galluzzo P, Contestabile M, Dell'Anna ML, Picardo M, Crispi S, Calogero RA, Piccolo MT, Arigoni M, Cantarella D, Boccellino M, Quagliuolo L, Ferretti G, Carlini P, Felici A, Boccardo F, Cognetti F, Baldi A.

Future Oncol. 2013 Sep;9(9):1375-88. doi: 10.2217/fon.13.99.

PMID:
23980684
23.

The noninflammatory role of high mobility group box 1/Toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells.

Conti L, Lanzardo S, Arigoni M, Antonazzo R, Radaelli E, Cantarella D, Calogero RA, Cavallo F.

FASEB J. 2013 Dec;27(12):4731-44. doi: 10.1096/fj.13-230201. Epub 2013 Aug 22.

PMID:
23970797
24.

miR-135b coordinates progression of ErbB2-driven mammary carcinomas through suppression of MID1 and MTCH2.

Arigoni M, Barutello G, Riccardo F, Ercole E, Cantarella D, Orso F, Conti L, Lanzardo S, Taverna D, Merighi I, Calogero RA, Cavallo F, Quaglino E.

Am J Pathol. 2013 Jun;182(6):2058-70. doi: 10.1016/j.ajpath.2013.02.046. Epub 2013 Apr 23.

25.

A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors.

Arigoni M, Barutello G, Lanzardo S, Longo D, Aime S, Curcio C, Iezzi M, Zheng Y, Barkefors I, Holmgren L, Cavallo F.

Angiogenesis. 2012 Jun;15(2):305-16. doi: 10.1007/s10456-012-9263-3. Epub 2012 Mar 17.

26.

Optimizing a massive parallel sequencing workflow for quantitative miRNA expression analysis.

Cordero F, Beccuti M, Arigoni M, Donatelli S, Calogero RA.

PLoS One. 2012;7(2):e31630. doi: 10.1371/journal.pone.0031630. Epub 2012 Feb 20.

27.

Oncoantigens for an immune prevention of cancer.

Bolli E, Quaglino E, Arigoni M, Lollini PL, Calogero R, Forni G, Cavallo F.

Am J Cancer Res. 2011;1(2):255-264. Epub 2010 Dec 20.

28.

A novel Dictyostelium RasGEF required for chemotaxis and development.

Arigoni M, Bracco E, Lusche DF, Kae H, Weeks G, Bozzaro S.

BMC Cell Biol. 2005 Dec 7;6:43.

29.

PET studies of 18F-memantine in healthy volunteers.

Ametamey SM, Bruehlmeier M, Kneifel S, Kokic M, Honer M, Arigoni M, Buck A, Burger C, Samnick S, Quack G, Schubiger PA.

Nucl Med Biol. 2002 Feb;29(2):227-31.

PMID:
11823128
30.

PET imaging of dopamine transporters in the human brain using [(11)C]-beta-CPPIT, a cocaine derivative lacking the 2 beta-ester function.

Schönbächler RD, Gucker PM, Arigoni M, Kneifel S, Vollenweider FX, Buck A, Burger C, Berthold T, Brühlmeier M, Schubiger PA, Ametamey SM.

Nucl Med Biol. 2002 Jan;29(1):19-27.

PMID:
11786272
31.

Simplified quantitative determination of cerebral perfusion reserve with H2(15)O PET and acetazolamide.

Arigoni M, Kneifel S, Fandino J, Khan N, Burger C, Buck A.

Eur J Nucl Med. 2000 Oct;27(10):1557-63.

PMID:
11083547
32.

Similarity and robustness of PET and SPECT binding parameters for benzodiazepine receptors.

Millet P, Graf C, Buck A, Walder B, Westera G, Broggini C, Arigoni M, Slosman D, Bouras C, Ibáñez V.

J Cereb Blood Flow Metab. 2000 Nov;20(11):1587-603.

PMID:
11083234
33.

Evaluation of serotonergic transporters using PET and [11C](+)McN-5652: assessment of methods.

Buck A, Gucker PM, Schönbächler RD, Arigoni M, Kneifel S, Vollenweider FX, Ametamey SM, Burger C.

J Cereb Blood Flow Metab. 2000 Feb;20(2):253-62.

PMID:
10698061
34.

Benzodiazepine-insensitive mice generated by targeted disruption of the gamma 2 subunit gene of gamma-aminobutyric acid type A receptors.

Günther U, Benson J, Benke D, Fritschy JM, Reyes G, Knoflach F, Crestani F, Aguzzi A, Arigoni M, Lang Y, Bluethmann H, Mohler H, Lüscher B.

Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7749-53.

35.

Stoichiometry of a recombinant GABAA receptor deduced from mutation-induced rectification.

Backus KH, Arigoni M, Drescher U, Scheurer L, Malherbe P, Möhler H, Benson JA.

Neuroreport. 1993 Dec 13;5(3):285-8.

PMID:
7507726
36.

[Final evaluation of the randomized multicenter study SAKK 40/81: adjuvant portal chemotherapy of curatively resected colorectal cancer].

Laffer U, Metzger U, Aeberhard P, Arigoni M, Arma S, Barras J, Egeli R, Martinoli S, Müller W, Schweizer W, et al.

Helv Chir Acta. 1992 Mar;58(5):755-8. German.

PMID:
1592650
37.

[Colostomy closure after Hartmann operation: functional results].

von Flüe M, Arigoni M, Vogt B.

Helv Chir Acta. 1992 Mar;58(5):741-5. German.

PMID:
1592648
38.

Randomized multicenter trial of adjuvant intraportal chemotherapy for colorectal cancer (SAKK 40/81). An interim report.

Metzger U, Laffer U, Aeberhard P, Arigoni M, Arma S, Barras J, Egeli R, Martinoli S, Mueller W, Schweizer W.

Acta Chir Scand. 1990 Jun-Jul;156(6-7):467-74.

PMID:
2114722

Supplemental Content

Loading ...
Support Center